GlassScriptPhysician profile
Margarita Chang
NPI 1841793155
$4,880.60
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,567 · 2022: $1,270 · 2023: $1,999 · 2024: $44.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,043.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,701.11 | 2023 | M22 |
| Esperion Therapeutics, INC. | $1,250.39 | 2021-2022 | |
| Amarin Pharma, INC. | $398.64 | 2021-2022 | |
| Glaxosmithkline, LLC. | $158.43 | 2021-2022 | |
| Novo Nordisk INC | $158.28 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $145.39 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.79 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $136.32 | 2021-2022 | |
| Abbvie INC. | $123.87 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.77 | 2021-2023 | Ofev, Jardiance, Stiolto Respimat |
| Ibsa Pharma INC. | $89.47 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $83.81 | 2021-2023 | Belsomra |
| Amgen INC. | $71.71 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $47.74 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $42.19 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $37.81 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $37.14 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.80 | 2022 | |
| Phadia US INC. | $20.67 | 2023 | Immunocap |
| Actelion Pharmaceuticals US, INC. | $20.52 | 2023 | Opsumit |
| Ardelyx, INC. | $19.26 | 2023 | Ibsrela |
| Eisai INC. | $15.32 | 2022 | |
| Pfizer INC. | $15.17 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margarita Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.